Paramount drag hides a working engine; the market's skepticism is overdone
Reported PAT of ₹27.6 Cr includes a ₹3.1 Cr one-time gain; adjusted profit of ₹24.5 Cr is the real number. Underneath, revenue grew 24.1%, EBITDA margins expanded 330 basis points, and technology is scaling. But group retention fell to 90.2% from 93-94%, and the market is pricing in prolonged recovery risk.
₹27.6 Cr
+21.9% YoY
₹3.1 Cr
−11.2% of reported PAT
₹24.5 Cr
−49.3% QoQ · 10.4% margin
₹236.5 Cr
+24.1% YoY
20.3%
+330 bps over 4 quarters
₹245.5 Cr
Debt-free; net worth ₹884.1 Cr
The real number
Medi Assist reported PAT of ₹27.6 Cr, a 21.9% year-on-year jump. But ₹3.1 Cr of that came from a one-time derivative gain on the Mayfair acquisition (increased stake to 91.75%). Strip that out, and adjusted PAT is ₹24.5 Cr — a 10.4% margin, solid but not exceptional. The quarter-on-quarter collapse of 49.3% reflects two things: Q4 FY26 seasonality (the prior base was artificially high) and integration drag from the Paramount acquisition still flowing through.
The story underneath is better. Revenue grew 24.1% year-on-year to ₹236.5 Cr, beating the industry's 14% growth and validating management's claim of market share gains. EBITDA margin expanded to 20.3%, up 330 basis points over the past four quarters — the highest quarterly result in the series and proof that the Paramount integration synergies are real and materializing. Free cash stands at ₹245.5 Cr, the company is debt-free, and DSO improved 4.5% year-on-year. The machine is working.
What changed on this call
Group grew 25.5% YoY (₹166 Cr, 70% of total) with 37.6% market share
Technology revenue ₹7.8 Cr at 55.5% YoY growth; 7 insurers contracted with first outcomes-based deal signed
Government revenue ₹28.5 Cr at 35.3% YoY growth; margin accretive
Paramount integration 95% migrated (claims); full completion Q2 FY27; 330 bps margin improvement already achieved
International down 5.2% YoY (₹10.1 Cr) — 'temporarily impacted' by travel/marine softness; Thailand tech contract live post-quarter
Group retention 90.2%, down 300–400 bps from historical 93–94% baseline; recovery expected but no timeline beyond 'FY27'
The call confirmed that the Paramount integration — the company's largest bet in years — is on track. Migration stands at 95% complete for group claims and 80% for retail. The 330-basis-point margin improvement over four quarters is not projected; it is delivered. Full completion in Q2 FY27 sets up another 250+ bps of margin upside from there to the company's target of 23% by year-end.
Technology is no longer a lab project. Seven insurers are now contracted (MAven, MAtrix, Magnum), the platform now administers ₹4,254 Cr of retail premiums (29% of market), and management signed its first outcomes-based contract tied to fraud, waste, and abuse savings. Revenue is only ₹7.8 Cr (3.3% of consolidated), but 55.5% growth from a low base suggests material upside if the insurer sales cycles close. Management has conversations with roughly half of the insurance industry.
The two new headwinds are real. Group retention fell to 90.2% from a historical 93–94% baseline — a 300–400 basis point drag from the Paramount onboarding and portfolio rationalization. Same-store growth remains stable at 7–8%, but customer attrition from the acquired book is masking it. Management says it will normalize through FY27 but offered no specific quarter. International revenue declined 5.2% year-on-year, buried in the segment and only discussed in Q&A. Travel, student, and marine volumes were softer in Q1; the company flagged this as temporary and is pivoting the model away from pure IPMI travel premiums toward technology-enabled access in new markets (Thailand contract live post-quarter, retail insurer travel contracts signed).
The bull-bear ledger
Revenue growth of 24.1% beats industry (14%); group 25.5%, government 35.3%, technology 55.5%
EBITDA margin at 20.3% with clear 330-bps improvement path already delivered; target 23% by year-end
Paramount integration 95% migrated; completion Q2 FY27 unlocks further margin recovery
Technology platform scaling: 7 insurer contracts, outcomes-based deals signed, ₹4,254 Cr premiums administered
Cash generation robust; debt-free balance sheet with ₹245.5 Cr free cash and ₹884.1 Cr net worth
Market share gains: group 37.6% (largest TPA), PSU PUM +28.9% vs −1.5% industry decline
Reported PAT includes ₹3.1 Cr one-time gain; adjusted profit of ₹24.5 Cr is 10.4% margin, not exceptional
Group retention fell to 90.2% from 93–94% baseline; 300–400 bps headwind from Paramount onboarding
Recovery timeline vague; management says normalization 'through FY27' but no specific quarter given
International down 5.2% YoY; travel-dependent model lacks diversification; recovery pace unclear
Technology at low base (3.3% of revenue); all 7 insurer contracts early-stage POCs; sales cycles longer than expected
PSU segment industry headwind (−1.5% YoY); 4 PSUs building in-house HITPA entities; premium migration risk if retention deteriorates further
Risks, ranked by severity
Group retention pressure
HighRetention fell 300–400 bps to 90.2% from 93–94% baseline due to Paramount onboarding and portfolio rationalization. If recovery extends beyond FY27, customer churn will erode growth. Same-store growth is stable (7–8%), but attrition masks it. New Chief TPA Officer hired to fix this, but timeline is vague. Largest segment (70% of revenue) is at risk.
International market volatility
MediumInternational revenue down 5.2% YoY; Q1 impacted by softness in student, leisure, marine. The pivot to tech + travel contracts (Thailand model) is promising but unproven. If recovery delays, international contribution (4.3% of revenue) stays depressed, and growth guidance misses.
Technology monetization
MediumTechnology revenue is only ₹7.8 Cr (3.3% of total) despite 55.5% YoY growth. All 7 insurer contracts are early-stage POCs; first outcomes-based deal terms undisclosed. Sales cycles longer than expected. Risk: growth rate decelerates as base scales, or insurer adoption stalls. Could be transformational if scaled, but proof of concept is still pending.
In-house TPA competition (PSU HITPA)
Medium4 PSUs are building in-house HITPA entities for TPA work. Risk: premium migration away from Medi Assist despite 37.6% group market share. Management downplayed risk (retention rates are proxy), but if HITPA becomes dominant, market share could erode. PSU segment already down 1.5% industry-wide.
Earnings quality dependency
MediumReported PAT includes ₹3.1 Cr one-time gain (11% of profit). Without such gains, adjusted PAT is pedestrian (₹24.5 Cr, 10.4% margin). If integration costs persist into H2, normalized profitability could be lower than headline numbers suggest.
Macroeconomic and regulatory
LowGroup health industry growth 14% YoY; PSU segment down 1.5%. Government scheme growth (35.3%) depends on policy continuity. IRDAI policyholder protection intent could impose operational constraints. But Medi Assist growing faster than market (24.1% vs 14%), so company is gaining share despite headwinds.
How the street sees it
The market's reaction was decidedly negative. On day 1 after the result announcement, the stock fell 3.4%. By day 3, it had fallen 3.84%. This was not a pop-and-fade; the market rejected the print. The stock is now trading at ₹350, down 39.2% from its all-time high of ₹575.55 and trading below all key moving averages — below the SMA20 (₹353.34), SMA50 (₹358.65), and SMA200 (₹395.96). Volume is increasing, a signal that institutional sellers are active. RSI at 57.9 is neutral, neither oversold nor overbought, so the downtrend is not yet extreme.
On the ownership front, domestic institutions (DII) are trimming. They held 47.24% in Q1 FY27 but trimmed by 195 basis points from 49.19% in Q4 FY26. Foreign institutions (FII) added 110 basis points to 25.42%. The promoters remain steady at 4.61%, offering no signal of conviction or concern. The DII exit is the tell: domestic money sees value deterioration from Paramount integration risks and customer churn, and they're moving to the exits before recovery is proven.
The market's skepticism is not unreasonable. Group retention at 90.2%, the headline-to-adjusted-PAT gap, and international weakness are real. But the market is also undershooting the fundamental recovery: the 330-bps EBITDA margin improvement is achieved, Paramount completion is in sight (Q2), and technology contracts are live. The stock's 39% drawdown from ATH is severe, and if Paramount integration normalizes and retention recovers in H2 FY27, the valuation becomes compelling. For now, the market's caution reflects legitimate execution risk rather than a broken story.
What to watch next
1 · Q2 group retention trend
Did group retention stabilize, improve toward 91–92%, or deteriorate further toward 89%? This is the single most important metric. If retention is stable or improving in Q2, the market will re-rate. If it deteriorates, the Paramount integration story breaks.
2 · Paramount full migration completion and margin recovery
Management targets Q2 FY27 for completion. If achieved and EBITDA margin visibly lifts above 20.3% (toward 21%+), the 330-bps synergy thesis is validated. This is a concrete event; watch the press release and Q2 call.
3 · International revenue inflection (H2 FY27)
Q1 was −5.2% YoY. Management expects recovery as student/travel/marine normalize and Thailand tech contracts ramp. If Q2 international returns to positive territory, the market regains confidence. If it stays negative, the international model reset is stalling.
The number to track
Adjusted PAT (stripping one-time gains). Reported PAT is ₹27.6 Cr in Q1, but adjusted is ₹24.5 Cr. Track the adjusted run-rate without one-time cushion. If adjusted PAT reaches ₹28–30 Cr by Q2–Q3, the integration recovery is real and the stock deserves a re-rate. If it stays at ₹24–25 Cr through H2, the margin expansion story is fragile and retention risk dominates.
Medi Assist is a steady business with real growth momentum and margin expansion, but it's being held back by post-acquisition execution headwinds. The reported profit of ₹27.6 Cr inflates the picture; adjusted PAT of ₹24.5 Cr is the real number, and QoQ it's down 49% due to integration drag and seasonality. The bull case—that Paramount synergies materialize and retention normalizes—is credible but not yet proven. The market's 39% drawdown from ATH and the DII's 195-basis-point exit reflect legitimate caution, not panic selling. The stock is neither a screaming buy nor a clear sell at ₹350; it's a 'wait for Q2 proof' story. Retention recovery and Paramount completion in Q2 will reset the narrative. Until then, the risk/reward slightly favors patience.
Medi Assist Q1FY27: PAT up 22% YoY to ₹27.6 Cr (~11% adjusted), OPM slips on Paramount mix
PAT +21.94% YoY · revenue +24.12% · margins compressing
₹236.52 Cr
+24.12% YoY
₹27.6 Cr
+21.94% YoY
11.17%
-0.3pp YoY
₹3.71
Medi Assist's consolidated PAT rose 22% YoY to ₹27.6 Cr on revenue of ₹236.5 Cr (+24% YoY), but the topline growth is largely inorganic: Paramount TPA was consolidated only from 1 July 2025, so it contributed nothing to the year-ago (Q1FY26) base and a full quarter this time — the like-for-like organic growth rate is materially lower than the headline 24%. Standalone PAT was ₹13.2 Cr on ₹59.0 Cr revenue with EPS ₹1.76; consolidated EPS was ₹3.71 (vs ₹7.33 last quarter, ₹3.18 a year ago). Sequentially, revenue slipped 2.3% and PAT fell 49% from ₹54.5 Cr, but that drop is distorted by a ~₹31.5 Cr one-off deferred-tax credit Q4FY26 booked against the Paramount TPA business-transfer scheme, so the QoQ decline overstates the underlying change.
Q1 FY-2027 vs prior quarters
Operating margin (OPM) compressed to 20.3% from 22.1% a year ago — a 175bp YoY squeeze — even as it improved 36bps sequentially from 19.9% last quarter. Net margin held up better, at 11.7% versus 11.4% a year ago, only because the effective tax rate fell to 20.9% from 25.8%; without that tax tailwind, bottom-line growth would have trailed revenue growth more visibly. The quarter also carried a ₹3.1 Cr one-off gain from remeasuring the derivative liability tied to the increased stake in Mayfair We Care, booked in other income. Stripping that out, adjusted PBT is ₹31.8 Cr and adjusted PAT is roughly ₹25.1 Cr — adjusted YoY PAT growth of ~11%, versus 22% reported, a meaningfully softer underlying trend.
The stock went into the print at ₹365, up 1.8% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters.
Management anticipates technology and international business growth to continue at or above FY26's strong pace, while the core business aims to grow in line with or better than the industry. No explicit margin guidance was provided, but the company highlighted recent quarterly EBITDA margin expansion and expects to rea
— This quarter: missed
Management's prior (Q4FY26) commentary pointed to continued quarterly EBITDA margin expansion as Paramount synergies land, expected to complete "within the next one to two quarters." This quarter's sequential OPM uptick is consistent with that, but the YoY compression means the promised expansion hasn't yet shown up against the comparable base, so on the primary year-on-year lens the read is closer to missed than met. No quarter-specific street/consensus estimate could be sourced, so vsStreet is unknown; a management press release commentary was not available at extraction time. Contemporaneous developments include completion of the Mayfair We Care stake increase to 91.75% (effective 1 July 2026, via a two-tranche ₹47.17 mn/₹28.51 mn advance) and the appointment of a new Chief TPA Officer (6 August 2026) — neither has a direct P&L read-through this quarter. The auditors' review carries an unchanged emphasis of matter on the ED search-and-seizure at MAITPA's Jharkhand offices, first flagged in FY26; management maintains there is no adverse impact and made no adjustment.
W1
Paramount TPA integration/synergy realization, which management (May 2026 call) said was on track for completion "within the next one to two quarters" — watch for OPM recovery toward the 22%+ level seen a year ago.
W2
Resolution of the Paramount TPA merger-by-absorption scheme, pending IRDAI clarifications sought after quarter-end.
W3
Durability of the ~21% effective tax rate this quarter, given Q4FY26's outsized PAT was itself largely a deferred-tax artifact.
Solid growth masked by integration drag; structural platform opportunity emerging
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Prior margin guidance (synergies, expansion) being met (330 bps delivered). Paramount integration on track. But international weakness and retention drag are new execution challenges.
Optimistic
next 1–2 quarters
Very Optimistic
multi-year
Core business (group 25.5%, government 35%, tech 55.5%) confirms guided growth. EBITDA margin trajectory (17.1%→20.3% over 4Q) validates Paramount synergies. BUT Q1 international -5.2%, PAT -49.3% QoQ, and group retention drop to 90.2% signal mid-term headwinds before long-term platform thesis (outcomes contracts, tech commercialization, international scale) materializes.
₹236.5 Cr
Revenue · +24.1% YoY₹27.6 Cr
Reported PAT · +21.9% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Group revenues grew 25.5% YoY with 29.5% premiums growth
METSegment shows ₹166 Cr, 25.5% YoY growth (70.2% of total ₹236.5 Cr)
Technology revenue grew 55.5% YoY, now 3.3% of consolidated
MET₹7.8 Cr at 55.5% growth = 3.3% of ₹236.5 Cr
Government grew 35% YoY with ₹28.5 Cr revenue
MET₹28.5 Cr at 35.3% growth; 12% of total
International temporarily impacted; Q1 down due to travel/marine softness
METInternational ₹10.1 Cr, -5.2% YoY decline acknowledged as temporary
EBITDA margin 20.3% with quarterly expansion from 17.1% (Q2) to 20.3% (Q1)
METOperating EBITDA ₹48 Cr on ₹236.5 Cr = 20.3% margin; progression verified
Group retention 90.2% reflecting post-acquisition transition challenges
OVERSTATEDDelivered result context not explicit on retention, but call explains 90.2% with portfolio rationalization and onboarding drag
Earnings quality
What changed since the last call
Paramount integration closer to completion
UpgradePrior guidance '1-2 quarters for completion.' Q1 shows 95% group claims, 80% retail claims migrated; full completion targeted Q2 FY27. 330 bps margin improvement already delivered over 4Q.
International business model reset
UpgradePrior guidance emphasized IPMI travel premium exposure. Now live in Thailand on tech platform (1 July 2026) and signed retail insurer travel contracts (50%+ market access). Yields 'multiple times higher' than India.
Technology commercialization validation
UpgradePrior: 7 insurers in pipeline. Now: 7 insurers contracted across MAven/MAtrix/Magnum. First outcomes-based contract signed (fraud, waste, abuse). Platform now 29% of administered retail premiums.
Group retention decline on Paramount drag
DowngradePrior implied 93-94% baseline retention. Q1 delivered 90.2% due to post-acquisition onboarding challenges and portfolio rationalization. Management commits to normalization through FY27 but no specific quarter.
International revenue trajectory paused
DowngradeQ1 -5.2% YoY (₹10.1 Cr) due to temporary softness in student, leisure, marine. Described as 'temporarily impacted' but no guidance on Q2 recovery timing.
The Q&A
Analysts pressed on organic growth (pre-Paramount), margin path to 23%, government working capital, and PSU HITPA risk. Management held firm on market share gains, deflected Paramount breakout as complex, and downplayed in-house TPA risk citing retention rates as proxy. Tone: confident, not defensive.
Execution priorities & risks — Sucrit Patil, Eyesight Fintrade
PartialThree priorities: (1) Transform India TPA to digital self-help; (2) Scale technology business with substantial pipeline; (3) Grow international beyond IPMI. No explicit risks named; deflected to regulatory intent alignment (policyholder protection).
Margin trajectory — Prakash Kapadia, Kapadia Financial
PartialTarget 23% by end-FY27 via Paramount integration completion. Government business margin accretive, collections safe. No explicit PAT guidance; deflected on adjusted EBITDA due to growth business investments.
Government segment cash flow — Prakash Kapadia
AnsweredGovernment collections 'safest' (government entities). DSO improved 4.5% YoY. No capping of government revenue; purely opportunistic. Mixed answer: reassured on collections but avoided direct working capital risk.
Organic growth pre-Paramount — Manjeet, Saamya Advisors
PartialComplex math over 4 quarters. Offered retention (90%), same-store growth (7-8%), new business additions as proxies. Refused to split Paramount vs organic. Reasonable deflection.
Outcomes-based contract mechanics — Manjeet
DodgedCannot share specifics on first contract. Compensation tied to fraud, waste, abuse outcomes. No numbers given.
Retail business trajectory — Navid Virani, Bastion Research
AnsweredNot plateaued, just a reporting distinction. TPA model = formal introduction. Platform = backend work + tech. Retail + tech revenue is true retail market share. Clear answer with nuance.
Consolidated business growth guidance — Navid Virani
PartialCore at par or faster than market (14%). Technology much faster (3.3% base, high growth potential). International multiple times higher yields. Government opportunistic. Did not quantify consolidated growth.
PSU HITPA risk — Dhiraj Aaswan, Incred Equities
PartialOperating same landscape 10+ years. Retention rates and regulatory choice mechanism (policyholder can request TPA) are proxies. Will find way to contribute. Downplayed risk confidently.
NPS Swasthya scheme opportunity — Sandeep Kothari, East Lane Capital
AnsweredHealth administrator for NPS pension scheme withdrawals. Role: platform connecting members, CRAs, insurance, network, payments. Potential for platform revenues and incremental TPA revenues as scheme scales. Clear explanation.
Technology platform sales cycle — Sandeep Kothari
AnsweredNot pushback, but sales cycles longer. Each insurer different workflows. Half of insurers in conversations/POCs. Can integrate to core systems (MAtrix) or as standalone components. Transparent on cycle complexity.
PSU group health market decline — Vikas Sharda, NT Asset Management
AnsweredYes, negative 1.5% for PSU group health. Medi Assist gained market share in both PSU and private segments.
Guidance
Core business at par or faster than industry (industry ~14% YoY)
HighQ1 FY27 delivered 24.1% consolidated (vs 14% industry). Group at 25.5%. Strategy: organic + M&A.
Technology to be meaningful contributor; currently 3.3% of consolidated
MediumGrowing 55.5% YoY. Management targeting higher % but no explicit FY27 revenue target given. Pipelines with 7+ insurers.
International to grow with new models (tech + travel); not constrained to IPMI
MediumQ1 down 5.2%; temporary per management. Thailand tech contract live (1 July); expect recovery. Yields 'multiple times' higher than India.
Return to 23% EBITDA margins by end FY27 (from 20.3% in Q1)
HighParamount integration on track; 330 bps improvement already achieved. Full migration Q2 FY27.
Technology margins 'double' usual TPA margins; pure outcomes-based contracts higher
MediumManagement cited but no specific %; tied to outcomes and scale. Early stage with 7 insurer contracts.
Risks the call surfaced
Customer retention pressure
HighGroup retention dropped 300-400 bps to 90.2% from historical 93-94% due to Paramount onboarding and portfolio rationalization. Risk: prolonged drag if recovery extends beyond FY27.
International market volatility
MediumInternational revenue declined 5.2% YoY (₹10.1 Cr). Q1 impacted by softness in student, leisure, marine volumes. Risk: recovery pace unclear; travel-dependent revenue model lacks diversification.
In-house TPA competition
Medium4 PSUs reportedly building in-house HITPA entities for TPA work. Risk: premium migration away from Medi Assist despite current 37.6% group market share and 90.2% retention.
Technology monetization risk
Medium7 insurers contracted but all in POC/pilot stage. First outcomes-based contract terms unclear. Technology at 3.3% of revenue; scaling to material contribution depends on closing larger deals.
Macroeconomic & regulatory
LowGroup health industry grew 14% YoY; PSU segment down 1.5%. Regulatory intent on policyholder protection could impose operational constraints. Government scheme payment predictability at risk if policy changes.
Management
Score 8/10. Clear on strategy (3 growth engines), transparent on headwinds (retention drop, international weakness). Quantified metrics granularly (186K pre-auths, 87K 0-wait discharges, ₹183 Cr fraud savings). Some deflection on specifics (Paramount organic breakout, depreciation detail). Paramount integration 330 bps margin improvement over 4Q; 95% claims migrated Q1. Core revenue 24.1% YoY (vs 14% industry). Technology 55.5% YoY growth (from 3.3% base). Group market share 37.6%; PSU gains despite industry down 1.5%. Track record credible.
1 · Q2 FY27
Paramount full migration to Medi Assist stack; expect further margin recovery
2 · H2 FY27
International non-travel contracts (Thailand model) ramp; expect growth reversal
3 · FY27 end
EBITDA margins back to 23% (historical pre-Paramount level)
BUT Q1 international -5.2%, PAT -49.3% QoQ, and group retention drop to 90.2% signal mid-term headwinds before long-term platform thesis (outcomes contracts, tech commercialization, international scale) materializes.